<DOC>
	<DOCNO>NCT01826214</DOCNO>
	<brief_summary>The study evaluate efficacy , safety tolerability two dosing schedule LDE225 patient relapsed/refractory acute leukemia elderly patient untreated acute leukemia .</brief_summary>
	<brief_title>Study Efficacy Safety LDE225 Adult Patients With Relapsed/Refractory Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Subjects must relapse primary refractory nonM3 acute myeloid leukemia relapse refractory nonTcell acute lymphoblastic leukemia untreated acute myeloid leukemia elderly patient . Performance status 0 , 1 2 per WHO classification . Adequate renal liver function . Adequate blood creatine kinase value ( CK &lt; 1.5ULN ) Allogeneic stem cell transplantation within last 4 month and/or active graft versus host disease require systemic immunosuppressant therapy , autologous stem cell transplantation within last 4 week . Patient immediate allogeneic stem cell transplantation treatment choice . Pregnant nursing ( lactate ) woman . Active CNS leukemic involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>leukemia</keyword>
	<keyword>acute</keyword>
	<keyword>LDE225</keyword>
	<keyword>adult patient</keyword>
	<keyword>relapsed/refractory</keyword>
</DOC>